الفهرس 
Aging ProcessOnly 14 pages are availabe for public view
 |  | from | 236 |  |  |
| | | from | 236 | | |
Abstract
Aging is implicated in many chronic diseases that are common killers around the world for example heart diseases, cerebrovascular disease and cancer, so, slowing down aging would simultaneously reduce the incidence and prevalence of all these diseases (Mackey, 2003).
Several studies have shown that biochemical markers of bone turnover assist in the assessment of osteoporotic risk and in monitoring the efficacy of treatment (Swaminathan, 2001). Considerable attention has been given to novel factors that help in cardiovascular risk assessment, including but not limited to the measurement of homocysteine, high sensitivity C-reactive protein and more detailed lipoprotein panels (Eyre et al., 2004). There is sufficient evidence that justify the practical use of fasting plasma glucose level for screening individuals at high risk for type 2 diabetes mellitus (American Diabetes Association, 2004). Recent evidence-based guidelines for early cancer detection have introduced policy changes that have implications for cancer screening (Smith et al., 2005).
The aging process is associated with significant decline in the levels of many hormones and trophic factors including estrogen, testosterone, growth hormone, insulin-like growth factor, melatonin and dehydroepiandrosterone. Hormone replacement therapy require monitoring of the hormonal levels and identification of the appropriate effective threshold, taking into consideration the possible side effects (Morley, 2003).